Literature DB >> 10576887

Short-lasting primary headaches: focus on trigeminal automatic cephalgias and indomethacin-sensitive headaches.

P J Goadsby1.   

Abstract

Short-lasting primary headache syndromes provides both a diagnostic challenge and considerable therapeutic reward. Primary short-lasting headaches broadly divide themselves into those associated with auto nomic symptoms, trigeminalautonomic cephalgias and those with little autonomic syndromes. The trigeminal-autonomic cephalgias include cluster headache and paroxysmal hemicranias, in which head pain and cranial autonomic symptoms are prominent. Consideration of short- lasting headaches, particularly in the context of the differential diagnosis between cluster headache and paroxysmal hemicrania leads to a consideration of indomethacin-sensitive headaches. There are a group of headaches, such as paroxysmal hemicrania and hemicrana continua , which have a curious and a very robust response to indomethacin. These headaches tend to be referred to neurologists as they are refractory to other treatments and thus are useful to know about.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10576887     DOI: 10.1097/00019052-199906000-00006

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  4 in total

1.  [Treatment and prophylaxis for cluster headaches and other trigeminal autonomic headaches. Revised recommendations of the German Migraine and Headache Society].

Authors:  A May; S Evers; A Straube; V Pfaffenrath; H C Diener
Journal:  Schmerz       Date:  2005-06       Impact factor: 1.107

Review 2.  [The window into headache research : what have we learned from functional and structural neuroimaging].

Authors:  A May
Journal:  Schmerz       Date:  2010-04       Impact factor: 1.107

Review 3.  [Headache attacks with ipsilateral autonomic symptoms].

Authors:  A May
Journal:  Schmerz       Date:  2004-10       Impact factor: 1.107

Review 4.  [Etiology and diagnostics of headaches and facial pain from the neurological point of view].

Authors:  M Teepker; K Schepelmann
Journal:  HNO       Date:  2007-07       Impact factor: 1.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.